/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Inozyme Pharma, Inc. ("Inozyme" or the "Company") (NASDAQ: INZY). Such...
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Inozyme Pharma, Inc. ("Inozyme" or the "Company") (NASDAQ: INZY). Such...
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Inozyme Pharma, Inc. ("Inozyme" or the "Company") (NASDAQ: INZY). Such...
Inozyme (INZY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
High labor costs, along with inflationary pressures, are likely to have weighed on DaVita's (DVA) fourth-quarter top line.
Wilson Sonsini Goodrich & Rosati, the premier provider of legal services to technology, life sciences, and growth enterprises worldwide, announced today that Jon Soderstrom is joining the firm as its chief...
BOSTON, July 26, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel...
- Rapid and significant increase in plasma pyrophosphate (PPi) levels observed in all three subjects in lowest dose cohort (0.2 mg/kg) – - INZ-701 was...
The consensus price target hints at a 308.5% upside potential for Inozyme Pharma, Inc. (INZY). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings...
New technology aims to expand testing to approximately 1,000 diseases and sequencing to 3.7 million newborns annually...